Following the latest in microcap news, articles, interviews, and more

INVESTOR ALERT: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Eagle Pharmaceuticals, Inc. to Contact Brower Piven

INVESTOR ALERT: Brower Piven Notifies Shareholders of Securities Class Action Lawsuit and Encourages Shareholders Who
Have Losses in Excess of $100,000 from Investment in Eagle Pharmaceuticals, Inc. to Contact Brower Piven

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been
commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals, Inc.
(Nasdaq: EGRX) (“Eagle” or the “Company”) securities during the period between February 23, 2016 through March 18, 2016, inclusive
(the “Class Period”). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have
until August 1, 2016 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from
investment in Eagle securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure
to disclose during the Class Period that the U.S. Food and Drug Administration (“FDA”) would not approve KANGIO™ (“KANGIO”), a
blood thinning drug, in its present form and would need additional information regarding the substances used in KANGIO.

According to the complaint, following a March 18, 2016 announcement by the Company that it had received a Completed Response
Letter from the FDA for its KANGIO New Drug Application, which requested further characterization of bivalirudin-related substances
in the drug, the value of Eagle shares declined significantly.

If you have suffered a loss from investment in Eagle securities purchased on or after February 23, 2016 and held through the
revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and
your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting
Brower Piven either by email at hoffman@browerpiven.com or by telephone
at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in
question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a
member of the class.

Brower Piven, A Professional Corporation

Charles J. Piven, 410-415-6616

1925 Old Valley Road

Stevenson, Maryland 21153

hoffman@browerpiven.com



Updated: June 13, 2016 — 11:15 pm
Copyright © EquityBuzz 2016